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Reply. We are grateful for the interest others have
shown in our paper, which allowed us to clarify
critical aspects of the case-control study designand the nature of our study population.
First, why did so few of the patients with hepatocellular
carcinoma (HCC) receive curative treatments? Does this
suggest that screening benefit was not observed because
curative treatments were not readily available in the Vet-
eran’s Affairs (VA) Healthcare System? It is important to
recognize that the cases of HCC included in the study were,
by definition, all fatal cases in whom the HCC was judged to
have caused death. Therefore, one would expect very few
of these patients to have received potentially curative
treatments, even if they were readily available; if they had
received a treatment that invariably cured HCC, they would
not have died of HCC. For example, in our study population
no patient with HCC who underwent liver transplantation
during the study period subsequently died of HCC, and
therefore no such patients were included in the study as
cases. This finding is not a reflection of a lack of availability
of curative treatments. The important point here is that the
proportions of patients with fatal HCC who received
different types of HCC treatment (shown in Table 2) are
clearly not representative of the corresponding pro-
portions among all patients with HCC in the VA Healthcare
System.
In addition, the reason that many patients with early
stage HCC do not receive potentially curative treatments is
the stringent eligibility criteria for liver transplantation and
many contraindications to surgical resection or even abla-
tion, even among patients judged by the Milan criteria to
have early-stage disease. For example, of 4867 unselected
patients (ie, not necessarily fatal) diagnosed with early-
stage HCC (within Milan criteria) in the Surveillance,
Epidemiology, and End Results registry in 2010–2011, most
received no potentially curative treatment (65.3%) and only 
a small minority received local tumor destruction (14.4%), 
surgical resection (10.2%), or liver transplantation 
(10.2%).1
Second, why investigate receipt of screening over a 4-
year period when screening is recommended every 6 
months? We would like to emphasize that, in a case-control 
study, the time period over which screening histories are 
compared between cases and controls is not the same as the 
recommended screening interval. The 4-year period, known 
as the “detectable preclinical phase,” was chosen because it 
was estimated to be the maximum time period during which 
the screening test could potentially have diagnosed an HCC 
before it presented clinically. This estimate was based on 
studies reporting that tumors with a median growth rate (ie, 
doubling time of 117 days) would take 3.2 years to grow 
from 1 cm (the minimum size potentially detectable by ul-
trasound) to 10 cm (a size generally expected to cause 
symptoms). We conducted additional analyses in which we 
considered screening tests performed within 1, 2, or 3 years 
from the index date. This was to account for the observation 
that, when different time periods yield different odds ratios, 
the lowest odds ratio (ie, the one that indicates the greatest 
survival benefit associated with screening) is likely to be the 
least biased.2 However, there was no difference in receipt of 
screening between cases and controls during the 1, 2, 3, or 4 
years before the index date.
Third, can we draw conclusions about the effectiveness 
of regular surveillance (ie, every 6 months) when the study 
patients received on average only 2.1 ultrasound examina-
tions over a 4-year period? Focusing on the low average 
number of ultrasound examinations is misleading. When the 
average is 2.1 ultrasound examinations over 4 years, it 
means that some patients were getting no ultrasound ex-
aminations (indeed w50% had no screening ultrasound 
examinations over 4 years), whereas many others received 
fairly frequent, “regular” ultrasound examinations. There-
fore, indirectly the study did indeed compare patients get-
ting no ultrasound examinations with those getting 
“regular” ultrasound examinations.
It is worth emphasizing that if all patients in the study 
were getting regular screening ultrasound examinations, we 
could not possibly have conducted the study. Any study of 
screening effectiveness requires a proportion of patients to 
be unscreened (ideally 50% for maximal power) so that 
they can be compared with those screened, ideally “regu-
larly.” This is indeed close to what we observed in our study.
The case-control study design has been used to study the 
effectiveness of the following screening tests, which were 
recommended at frequent intervals, just like HCC screening: 
fecal occult blood testing for colorectal cancer,3 Pap smears 
for cervical cancer,4 breast self-examination for breast 
ca,ncer5 skin self-examination for melanoma,6 and digital 
rectal examination for prostate cancer.7 Some of these case-
control studies reported associations between screening 
and lower cancer-related mortality (eg, fecal occult blood 
testing,3 Pap smear,4 skin self-examination6), others did not 
(eg, digital rectal examination7), and others had mixedfindings (eg, breast self-examination5). Therefore, there is
no inherent limitation in the case-control study design that
precludes it from identifying a positive effect on cancer-
related mortality of a screening test that is meant to be
administered at frequent intervals, if such an effect truly
exists.
Fourth, why not compare those who received no
screening versus those who received screening twice per
year as per American Association for the Study of Liver
Diseases guidelines? We believe that a comparison between
those receiving no screening versus screening twice per
year would result in a spuriously low odds ratio associated
with multiple (or “regular”) screening even in the absence of
any effective therapy for screen-detected cancers. This is
explained in the Statistical Analysis section of our article
and in our prior publications.8,9
Fifth, what if the quality of the ultrasound examinations
or their interpretation was poor? It is impossible to
retrospectively assess the quality of ultrasound examina-
tions. What is highly likely is that the quality of the ultra-
sound examinations in our study, which were performed in
a very large number of hospitals around the country, more
closely reflects the quality of ultrasound examinations
performed in contemporary clinical practice in the United
States than, say, the quality of the ultrasound examinations
performed by a single, dedicated expert radiologist in a
clinical trial.
Sixth, was the study underpowered to look at
screening by ultrasound examination and/or alpha feto-
protein? It was pointed out that we estimated in our po-
wer calculations that 70% of the controls would have
received screening by serum alpha fetoprotein or ultra-
sound examination, whereas in fact the observed rate was
54%, and this was taken as evidence that the study must
be underpowered. In fact, the opposite is true: a case-
control study has the highest power for a given sample
size when the frequency of exposure in the control group
is close to 50%.
In summary, it is erroneous to attribute the lack of
screening-related survival benefit in our study to lack of
“regular screening” or unavailability of potentially curative
treatments based on the reported results.
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